Abstract

Existing HIV-1 immunogens are unable to effectively elicit broadly reactive neutralizing antibodies (NAb) that are likely necessary for an optimally effective vaccine. Rare neutralizing monoclonal antibodies (mAbs) targeting the envelope glycoprotein exist and uncommon sera from HIV-1-infected individuals can neutralize diverse HIV-1 strains. From a well characterized patient cohort, we have studied over 100 HIV+ sera to identify those displaying potent and broad HIV-1 neutralization. Several sera with broad neutralizing activity, along with some sera with weak neutralizing activity, have been mapped to understand what epitopes on the virus are targetted by antibodies. For several potent sera, we found that adsorption with gp120 derived from a single clade B isolate diminished serum neutralizing activity against cross-clade viral strains. A gp120 CD4 binding defective point mutant displayed substantially reduced adsorption capacity. Selective antibody elution and adsorption revealed a fraction of antibodies directed against the CD4 receptor binding site (CD4bs) that were able to neutralize diverse HIV-1 strains. Previously unidentified antibodies to the CD4bs exist in some HIV-1 sera, suggesting that new approaches to present this conserved region of gp120 to the immune system may result in vaccine immunogens that elicit broadly NAbs.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005091-02
Application #
7732784
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2008
Total Cost
$305,129
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
United States
Zip Code